2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
April 21st 2022
Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.
January 20th 2021
Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.
January 13th 2021
Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.
January 5th 2021
Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.
December 21st 2020
Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.